| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/02/2009 | US20090169574 Heteroclitic analogs and related methods |
| 07/02/2009 | US20090169573 T-Cell Stimulatory Peptides From The Melanoma-Associated Chondroitin Sulfate Proteoglycan And Their Use |
| 07/02/2009 | US20090169572 Methods for damaging cells using effector functions of anti-cdh3 antibodies |
| 07/02/2009 | US20090169571 Selected ma motifs to include cell death and/or apoptosis |
| 07/02/2009 | US20090169570 Methods and agents for improving targeting of cd138 expressing tumor cells |
| 07/02/2009 | US20090169569 APO-2L receptor agonist and CPT-11 synergism |
| 07/02/2009 | US20090169568 Antigenic Complex for the Diagnosis and Treatment of Porphyromonas Gingivalis Infection |
| 07/02/2009 | US20090169567 Basic group-containing compound and use thereof |
| 07/02/2009 | US20090169566 Bioactive compositions |
| 07/02/2009 | US20090169565 Neutrokine-alpha antibodies and methods of use thereof |
| 07/02/2009 | US20090169564 Stimulus Inducible Protein Kinase Complex and Methods of Use Therefor |
| 07/02/2009 | US20090169563 Administering monoclonal antibody or an antigen-binding portion thereof that specifically binds to and activates human CD40; Gene therapy; nucleic acid coding immunoglobulins; anticancer agents |
| 07/02/2009 | US20090169562 Human Binding Molecules Having Killing Activity Against Enterococci and Uses Thereof |
| 07/02/2009 | US20090169561 monoclonal antibodies that bind to interferon-inducible-protein-10 (IP-10, CXCL10); immune system disorders; autoimmune or inflammatory disorders |
| 07/02/2009 | US20090169560 Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof |
| 07/02/2009 | US20090169559 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| 07/02/2009 | US20090169558 Bicyclic aromatic compounds useful as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 |
| 07/02/2009 | US20090169557 Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies |
| 07/02/2009 | US20090169556 Vascular endothelial cell growth factor antagonists |
| 07/02/2009 | US20090169555 Administering the kinase to regulate mitogenesis, apoptosis, neuronal development, chemotaxis, angiogenesis or an inflammatory response inclding developmental retardation, excessive apoptosis, cancer, restenosis and diabetic neuropathy; screening for drugs that stimulate or inhibit lipid phosphorylation |
| 07/02/2009 | US20090169554 Polypeptides of Leishmania Major and Polynucleotides Encoding Same and Vaccinal, Therapeutical and Diagnostic Applications Thereof |
| 07/02/2009 | US20090169553 Novel Protein Fusion/Tag Technology |
| 07/02/2009 | US20090169552 NEGATIVE IMMUNOMODULATION OF IMMUNE RESPONSES BY ERp5 |
| 07/02/2009 | US20090169551 Methods and compositions for activating or inhibiting vegf-d and vegf-c |
| 07/02/2009 | US20090169550 Therapy of rituximab-refractory rheumatoid arthritis patients |
| 07/02/2009 | US20090169549 Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use |
| 07/02/2009 | US20090169548 Binding molecules |
| 07/02/2009 | US20090169547 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 07/02/2009 | US20090169546 For inhibiting the release of a proinflammatory cytokine from a vertebrate cell; sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury |
| 07/02/2009 | US20090169545 5-ht4 receptor antagonists for the treatment of heart failure |
| 07/02/2009 | US20090169544 Formulation |
| 07/02/2009 | US20090169543 Method for regulating immune function in primates using the Foxp3 protein |
| 07/02/2009 | US20090169542 Modulators of neuronal regeneration |
| 07/02/2009 | US20090169541 Humanized Anti-CCR2 Antibodies and Methods of Use Therefor |
| 07/02/2009 | US20090169540 Use Of An Antagonist Of Epac For Treating Human Cardiac Hypertrophy |
| 07/02/2009 | US20090169529 Compositions and methods for immunostimulatory rna oligonucleotides |
| 07/02/2009 | US20090169506 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 07/02/2009 | US20090169505 Novel vaccines against multiple subtypes of influenza virus |
| 07/02/2009 | US20090169503 Dna-based vaccination of retroviral-infected individuals undergoing treatment |
| 07/02/2009 | US20090169498 Controlled Release Gels |
| 07/02/2009 | US20090169478 In Vivo Imaging and Therapy with Magnetic Nanoparticle Conjugates |
| 07/02/2009 | US20090169477 Delaying or preventing onset of multiple sclerosis |
| 07/02/2009 | US20090169476 Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| 07/02/2009 | US20090169472 Methods and compositions for treating immune disorders |
| 07/02/2009 | DE19963612B4 Neue spannungsabhängige Kaliumkanäle aus der Kv4-Familie sowie deren Verwendung zur Entwicklung von Therapeutika New voltage-dependent potassium channels of the Kv4 family, as well as their use for the development of therapeutics |
| 07/02/2009 | CA2710611A1 Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine |
| 07/02/2009 | CA2710600A1 Recombinant rsv antigens |
| 07/02/2009 | CA2710483A1 Methods and agents for improving targeting of cd138 expressing tumor cells |
| 07/02/2009 | CA2710471A1 Immunoconjugates targeting cd138 and uses thereof |
| 07/02/2009 | CA2710350A1 Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof |
| 07/02/2009 | CA2710347A1 Pm-2 antibodies and methods for treating metastasis |
| 07/02/2009 | CA2709927A1 Mutant forms of streptolysin o |
| 07/02/2009 | CA2709645A1 Sm-protein based secretion engineering |
| 07/02/2009 | CA2709500A1 Type iii secretion system component protein pa1698 of pseudomonas aeruginosa |
| 07/02/2009 | CA2709430A1 Bivalent, bispecific antibodies |
| 07/02/2009 | CA2709347A1 Bivalent, bispecific antibodies |
| 07/02/2009 | CA2709345A1 Bivalent, bispecific antibodies |
| 07/02/2009 | CA2709041A1 Vaccines for malaria |
| 07/02/2009 | CA2709023A1 Bivalent, bispecific antibodies |
| 07/02/2009 | CA2708879A1 Allergens and allergoids from bee venom |
| 07/02/2009 | CA2708878A1 Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| 07/02/2009 | CA2708740A1 Hepatitis c virus antibodies |
| 07/02/2009 | CA2708718A1 Vaccine |
| 07/02/2009 | CA2708716A1 Vaccines for malaria |
| 07/02/2009 | CA2708686A1 Methods of inhibiting tumor growth using ttk antagonists |
| 07/02/2009 | CA2708566A1 Edible product having an immunostimulating effect |
| 07/02/2009 | CA2708407A1 Humanized anti-human cd34 antibody, the preparation method and uses thereof |
| 07/02/2009 | CA2708074A1 Non-aggregating human vh domains |
| 07/02/2009 | CA2706363A1 Method and compositions for cutaneous immunisation |
| 07/02/2009 | CA2706020A1 Allergen desensitization method |
| 07/02/2009 | CA2705444A1 Modified influenza virus |
| 07/01/2009 | EP2075582A2 Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
| 07/01/2009 | EP2075346A2 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 07/01/2009 | EP2075334A1 EG-VEGF nucleic acids and polypeptides and methods of use |
| 07/01/2009 | EP2075258A1 Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same |
| 07/01/2009 | EP2075255A1 Human FGF-23 gene and gene expression products |
| 07/01/2009 | EP2075008A2 Sensitizing cells for apoptosis by selectively blocking cytokines |
| 07/01/2009 | EP2075007A2 Treatment for Alzheimer's disease |
| 07/01/2009 | EP2075006A1 Aquatic nervous necrosis virus (NNV) vaccine and manufacture method thereof |
| 07/01/2009 | EP2075005A1 Ipv-dpt vaccine |
| 07/01/2009 | EP2074149A2 Compositions and methods relating to glucagon receptor antibodies |
| 07/01/2009 | EP2074148A1 Novel antiproliferation antibodies |
| 07/01/2009 | EP2074147A1 Antibodies against ccr5 and uses thereof |
| 07/01/2009 | EP2074146A2 Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor |
| 07/01/2009 | EP2073898A1 Complement inhibition for improved nerve regeneration |
| 07/01/2009 | EP2073851A1 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 07/01/2009 | EP2073844A2 Methods of treating systemic lupus erythematosus |
| 07/01/2009 | EP2073843A2 Methods of diagnosing, treating, or preventing plasma cell disorders |
| 07/01/2009 | EP2073842A2 Use of human cells of myeloid leukaemia origin for expression of antibodies |
| 07/01/2009 | EP2073841A2 Manufacture of booster vaccines having reduced antigen doses |
| 07/01/2009 | EP2073840A2 Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
| 07/01/2009 | EP2073839A2 A vaccine for chikungunya virus infection |
| 07/01/2009 | EP2073838A1 Therapeutic vaccine comprising mycobacterial heat shock protein 70 |
| 07/01/2009 | EP2073837A2 Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer |
| 07/01/2009 | EP2073833A2 Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
| 07/01/2009 | EP2073827A2 Multiple sclerosis therapy |
| 07/01/2009 | EP2036574A4 Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
| 07/01/2009 | EP1684770B1 Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer |
| 07/01/2009 | EP1673633B1 Method for detecting feline immunodeficiency virus |
| 07/01/2009 | EP1673106B1 Optimized expression of hpv 45 l1 in yeast |